Molecular Design Properties of OxyVita Hemoglobin, a New Generation Therapeutic Oxygen Carrier: A Review
Source abstract
Abstract
OxyVita Hb is a new generation hemoglobin based oxygen carrier (HBOC) produced through modification of a zero-linked polymerization mechanism using activators which incorporate cross-linked bovine tetramer hemoglobin into “super-polymeric” macromolecules (Average molecular weight = 17 MDa) for the purpose of oxygen delivery when whole blood or packed red cells are not available. This molecular design approach was generated in order to address several fundamental biochemical and physiological weaknesses of previous generations of HBOCs. Observation during pre-clinical and clinical studies provided evidence that these early generation acellular HBOCs were directly associated with loss of retention within the circulatory system, extravasation across endothelial tissue membranes due to their small molecular size leading to arterial and venous vasoconstriction with coupled increases in mean arterial pressure (MAP). The inherent increase in molecular size and structural stability of the OxyVita Hb is a direct response to addressing these serious weaknesses that have occurred during the evolution of HBOC development within the past two decades. The nature of the zero-linked synthetic route eliminates any chemical linkers remaining in the product, eliminating side reaction concerns, such as reversibility and decomposition due to weak chemical bonds, dependency on temperature and pressure, and residual toxicity.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Hemoglobin structure and function · Heme Oxygenase-1 and Carbon Monoxide · High Altitude and Hypoxia
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemistry, State University of New York, New Paltz, NY 12561, USA
OXYVITA, Inc., New Windsor, NY 12553, USA
References (29)
Show source-provided references
1. Cell-free oxygen carriers: Scientific foundations, clinical development, and new directions10.1016/j.bbapap.2008.04.032 ↗
2. First-generation blood substitutes: What have we learned? Biochemical and physiological perspectives10.1517/14712598.7.5.665 ↗
3. Red cell substitutes10.1053/j.seminhematol.2006.09.013 ↗
4. Blood substitutes: An overview and perspective
5. Acellular invertebrate hemoglobins as model therapeutic oxygen carriers: Unique redox potentials10.1080/10731190600974491 ↗
6. Low resolution crystal structure of Arenicola erythrocruorin: Influence of coiled coils on the architecture of a megadalton respiratory protein10.1016/j.jmb.2006.10.016 ↗
7. Lumbricus erythrocruorin at 3.5 A resolution: Architecture of a megadalton respiratory complex10.1016/j.str.2006.05.011 ↗
8. All hemoglobin-based oxygen carriers are not created equal10.1016/j.bbapap.2007.12.009 ↗
9. Basic science focus on blood substitutes: Summary of the NHLBI division of blood diseases and resources working group workshop10.1111/j.1537-2995.2007.01604.x ↗
10. Progress in the development of RBC substitutes10.1046/j.1537-2995.2001.41020287.x ↗
11. Hemoglobin-based oxygen carriers: Current status and future directions10.1111/j.1537-2995.2009.02356.x ↗
12. Oxygen therapeutics: Can we tame hemoglobin?10.1038/nrd1307 ↗
13. NO scavenging and the hypertensive effect of hemoglobin-based oxygen carriers10.1016/j.freeradbiomed.2003.11.030 ↗
14. Razynska, A., and Bucci, E. (1998). Zero-link polymerization: A new class of polymeric hemoglobins. Blood Substit. Present Future Perspect., 265–279.10.1016/B978-044420524-7/50022-9 ↗
15. Vascular response to infusions of a nonextravasating hemoglobin polymer10.1152/japplphysiol.00191.2002 ↗
16. Cerebrovascular response to decreased hematocrit: Effect of cellfree hemoglobin, plasma viscosity, and CO210.1152/ajpheart.00077.2003 ↗
17. Decreased damage from transient focalcerebral ischemia by transfusion of zero-linked hemoglobin polymers in mouse10.1161/STROKEAHA.108.526731 ↗
18. Low-volume resuscitation cocktail extends survival after severe hemorrhagic shock10.1097/shk.0b013e31802eb779 ↗
19. Does OxyVita, a new-generation hemoglobin-based oxygen carrier, or Oxyglobin acutely interfere with coagulation compared with normal saline or 6% Hetastarch? A ex vivo thromboelastography study10.1053/j.jvca.2007.02.016 ↗
20. Zero-length crosslinking procedure with the use of active esters10.1016/0003-2697(90)90267-D ↗
21. Enhancement by N-hydroxysulfosuccinimide of water-soluble carbodiimide-mediated coupling reactions10.1016/0003-2697(86)90176-4 ↗
22. Development of zero-linked polymers of hemoglobin, which do not Extravasate and do not induce Pressure increases upon infusion10.1080/10731190600974277 ↗
23. Effects of cross-linking and zero-link polymerization on oxygen transport and redox chemistry of bovine hemoglobin10.1016/j.bbapap.2009.04.008 ↗
24. Structural and redox behavior of OxyVita Hb, a zero-linked polymeric hemoglobin: Comparison with natural acellular polymeric hemoglobins10.3109/10731191003634562 ↗
25. Physicochemical characteristics of OxyVita hemoglobin, a zero-linked polymer: Liquid and powder preparations10.3109/10731199.2010.501753 ↗
26. Diagnostic significance of methemoglobin determination in colorless cerebrospinal fluid10.1093/clinchem/38.8.1404 ↗
27. Evaluation of multiwavelength derivative spectra for quantitative applications in clinical chemistry10.1093/clinchem/29.9.1673 ↗
28. Appearance of dissociable and crosslinked hemoglobins in renal hylar lymph10.1067/mlc.2000.106458 ↗
29. Transport of macromolecules across microvascular walls: The two pore theory